| Diabetes Mellitus
Rezgovlar vs Semglee
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Rezvoglar vs Semglee with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSemglee has a higher rate of injection site reactions vs Rezvoglar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Semglee but not Rezvoglar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rezvoglar
Semglee
At A Glance
SC injection
Once daily
Long-acting insulin analog
SC injection
Once daily
Long-acting insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus, Type 1 Approximately one-third of total daily insulin requirements SC once daily at the same time every day; use short-acting premeal insulin for the remainder.
Diabetes Mellitus, Type 2 0.2 units/kg or up to 10 units SC once daily in insulin-naive patients, adjusted based on metabolic needs and blood glucose monitoring results.
Diabetes Mellitus, Type 1 Approximately one-third of total daily insulin requirements SC once daily at the same time each day; use concomitantly with short-acting premeal insulin.
Diabetes Mellitus, Type 2 0.2 units/kg or up to 10 units SC once daily at the same time each day for insulin-naive patients; individualize based on metabolic needs and glycemic goals.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin glargine products or any excipient in REZVOGLAR
- Episodes of hypoglycemia
- Hypersensitivity to insulin glargine products or any excipient in Semglee
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, infection, accidental injury, headache, retinal vascular disorder
Serious Severe hypoglycemia, anaphylaxis, angioedema, bronchospasm, hypotension, shock, hypokalemia, lipodystrophy
Postmarketing Localized cutaneous amyloidosis, medication errors with inadvertent insulin substitution, hyperglycemia or hypoglycemia related to injections into amyloidosis-affected sites
Most common (>=5%) Upper respiratory tract infection, infection, accidental injury, headache
Serious Severe hypoglycemia, anaphylaxis and generalized hypersensitivity reactions, hypokalemia, peripheral edema, lipodystrophy
Postmarketing Medication errors with rapid-acting insulins administered instead of insulin glargine, localized cutaneous amyloidosis at injection site
Pharmacology
Long-acting human insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, lipolysis, and proteolysis while enhancing protein synthesis.
Insulin glargine-yfgn is a long-acting human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production; it also inhibits lipolysis and proteolysis and enhances protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rezvoglar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Semglee
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (3/12) · Qty limit (6/12)
UnitedHealthcare
Rezvoglar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (2/8)
Semglee
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Rezvoglar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Semglee
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rezvoglar.
No savings programs available for Semglee.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RezvoglarView full Rezvoglar profile
SemgleeView full Semglee profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.